Compounds > kb 130015
Page last updated: 2024-11-11

kb 130015

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

KB 130015: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9872203
CHEMBL ID157885
SCHEMBL ID3212510
MeSH IDM0414663

Synonyms (25)

Synonym
kb130015
kb 130015
kb-130015
2-methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)benzofuran
2-(2,6-diiodo-4-((2-methylbenzofuran-3-yl)methyl)phenoxy)acetic acid
bdbm50108807
[2,6-diiodo-4-(2-methyl-benzofuran-3-ylmethyl)-phenoxy]-acetic acid
CHEMBL157885 ,
147030-48-6
9YA9HD8JR2 ,
acetic acid, 2-(2,6-diiodo-4-((2-methyl-3-benzofuranyl)methyl)phenoxy)-
2-[2,6-diiodo-4-[(2-methyl-1-benzofuran-3-yl)methyl]phenoxy]acetic acid
gtpl7659
SCHEMBL3212510
unii-9ya9hd8jr2
acetic acid, (2,6-diiodo-4-((2-methyl-3-benzofuranyl)methyl)phenoxy)-
OLIKCJUMYWSDIV-UHFFFAOYSA-N ,
2-[2,6-diiodo-4-(2-methyl-1-benzofuran-3-ylmethyl)phenoxy]acetic acid
AKOS030240473
Q27893049
kb 130015; kb130015
BCP33047
acetic acid, 2-[2,6-diiodo-4-[(2-methyl-3-benzofuranyl)methyl]phenoxy]-
HY-120026
Z3247249354

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In summary, 7 appears to be less toxic than amiodarone while maintaining its electrophysiologic properties consistent with antiarrhythmic activity."( Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
Carlsson, B; Li, YL; Malm, J; Mellin, C; Nilsson, S; Singh, BN; Temciuc, M, 2002)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thyroid hormone receptor alphaHomo sapiens (human)IC50 (µMol)3.73330.00000.35494.5000AID213170; AID240602; AID241132
Thyroid hormone receptor betaHomo sapiens (human)IC50 (µMol)4.85720.00000.50185.1286AID213181; AID240579; AID241112; AID299948
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
cartilage condensationThyroid hormone receptor alphaHomo sapiens (human)
ossificationThyroid hormone receptor alphaHomo sapiens (human)
regulation of thyroid hormone mediated signaling pathwayThyroid hormone receptor alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIThyroid hormone receptor alphaHomo sapiens (human)
transcription by RNA polymerase IIThyroid hormone receptor alphaHomo sapiens (human)
learning or memoryThyroid hormone receptor alphaHomo sapiens (human)
regulation of heart contractionThyroid hormone receptor alphaHomo sapiens (human)
female courtship behaviorThyroid hormone receptor alphaHomo sapiens (human)
response to coldThyroid hormone receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayThyroid hormone receptor alphaHomo sapiens (human)
negative regulation of RNA polymerase II transcription preinitiation complex assemblyThyroid hormone receptor alphaHomo sapiens (human)
erythrocyte differentiationThyroid hormone receptor alphaHomo sapiens (human)
thyroid gland developmentThyroid hormone receptor alphaHomo sapiens (human)
regulation of myeloid cell apoptotic processThyroid hormone receptor alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionThyroid hormone receptor alphaHomo sapiens (human)
positive regulation of female receptivityThyroid hormone receptor alphaHomo sapiens (human)
regulation of lipid catabolic processThyroid hormone receptor alphaHomo sapiens (human)
type I pneumocyte differentiationThyroid hormone receptor alphaHomo sapiens (human)
positive regulation of cold-induced thermogenesisThyroid hormone receptor alphaHomo sapiens (human)
negative regulation of DNA-templated transcription initiationThyroid hormone receptor alphaHomo sapiens (human)
thyroid hormone mediated signaling pathwayThyroid hormone receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIThyroid hormone receptor alphaHomo sapiens (human)
cell differentiationThyroid hormone receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayThyroid hormone receptor alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayThyroid hormone receptor betaHomo sapiens (human)
DNA-templated transcriptionThyroid hormone receptor betaHomo sapiens (human)
sensory perception of soundThyroid hormone receptor betaHomo sapiens (human)
negative regulation of female receptivityThyroid hormone receptor betaHomo sapiens (human)
regulation of heart contractionThyroid hormone receptor betaHomo sapiens (human)
female courtship behaviorThyroid hormone receptor betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIThyroid hormone receptor betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor betaHomo sapiens (human)
retinal cone cell developmentThyroid hormone receptor betaHomo sapiens (human)
type I pneumocyte differentiationThyroid hormone receptor betaHomo sapiens (human)
cellular response to thyroid hormone stimulusThyroid hormone receptor betaHomo sapiens (human)
retinal cone cell apoptotic processThyroid hormone receptor betaHomo sapiens (human)
retinoic acid receptor signaling pathwayThyroid hormone receptor betaHomo sapiens (human)
cell differentiationThyroid hormone receptor betaHomo sapiens (human)
thyroid hormone mediated signaling pathwayThyroid hormone receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIThyroid hormone receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingThyroid hormone receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificThyroid hormone receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityThyroid hormone receptor alphaHomo sapiens (human)
nuclear receptor activityThyroid hormone receptor alphaHomo sapiens (human)
protein bindingThyroid hormone receptor alphaHomo sapiens (human)
zinc ion bindingThyroid hormone receptor alphaHomo sapiens (human)
TBP-class protein bindingThyroid hormone receptor alphaHomo sapiens (human)
protein domain specific bindingThyroid hormone receptor alphaHomo sapiens (human)
chromatin DNA bindingThyroid hormone receptor alphaHomo sapiens (human)
thyroid hormone bindingThyroid hormone receptor alphaHomo sapiens (human)
general transcription initiation factor bindingThyroid hormone receptor alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingThyroid hormone receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificThyroid hormone receptor betaHomo sapiens (human)
transcription coactivator bindingThyroid hormone receptor betaHomo sapiens (human)
DNA bindingThyroid hormone receptor betaHomo sapiens (human)
DNA-binding transcription factor activityThyroid hormone receptor betaHomo sapiens (human)
nuclear receptor activityThyroid hormone receptor betaHomo sapiens (human)
protein bindingThyroid hormone receptor betaHomo sapiens (human)
zinc ion bindingThyroid hormone receptor betaHomo sapiens (human)
enzyme bindingThyroid hormone receptor betaHomo sapiens (human)
chromatin DNA bindingThyroid hormone receptor betaHomo sapiens (human)
thyroid hormone bindingThyroid hormone receptor betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingThyroid hormone receptor betaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingThyroid hormone receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusThyroid hormone receptor alphaHomo sapiens (human)
nucleoplasmThyroid hormone receptor alphaHomo sapiens (human)
cytosolThyroid hormone receptor alphaHomo sapiens (human)
chromatinThyroid hormone receptor alphaHomo sapiens (human)
nucleusThyroid hormone receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexThyroid hormone receptor alphaHomo sapiens (human)
nucleoplasmThyroid hormone receptor betaHomo sapiens (human)
nuclear bodyThyroid hormone receptor betaHomo sapiens (human)
RNA polymerase II transcription regulator complexThyroid hormone receptor betaHomo sapiens (human)
chromatinThyroid hormone receptor betaHomo sapiens (human)
nucleusThyroid hormone receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID169949Effects on liver was determined from serum aspartate aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 111+/-21)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID190486Serum concentrations of T4 in rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 33.1+/-5.00)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID170074Effects on liver was determined from serum aspartate aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 111+/-21)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169946Effects on liver was determined from serum aspartate aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 106+/-18)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID73842Action potential amplitude of compound on guinea pig papillary muscles after twenty days of daily i.p. injection of 40 mg/kg Control = 115)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID240579Inhibitory activity against human TRAFbeta2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor.
AID173087Effects on liver was determined from serum cholesterol levels in male (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 0.67+/-0.13)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169915Effects on liver was determined from serum alanine aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 23+/-5)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169917Effects on liver was determined from serum alanine aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 30+/-3)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID190482Serum concentrations of T3 in rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 0.74+/-0.15)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169950Effects on liver was determined from serum aspartate aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 111+/-21)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID173084Effects on liver was determined from serum cholesterol levels in female (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 0.73+/-0.05)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID45735Antagonism of compound towards thyroid response element (TRAF beta) in CHO-K1 cells2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169914Effects on liver was determined from serum alanine aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 23+/-5)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID190487Serum concentrations of Thyrotropin in rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 11.00+/-1.97)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID77825Vmax of the action potential amplitude in guinea pig papillary muscles after twenty days of daily i.p. injection of 40 mg/kg Control = 205)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID213181Concentration required to inhibit 50% of binding of [125I]T3 to human Thyroid hormone receptor beta 1 in CHO-K1 cells2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID241112Inhibitory activity against human Thyroid hormone receptor beta2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor.
AID299948Inhibition of human thyroid hormone receptor beta 12007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
QSAR study of selective ligands for the thyroid hormone receptor beta.
AID77056Ratio of action potential duration (APD90/APD50) in guinea pig papillary muscles after twenty days of daily i.p. injection of 40 mg/kg Control = 1.10)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169948Effects on liver was determined from serum aspartate aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 106+/-18)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID190489Serum concentrations of Thyrotropin in rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 11.00+/-1.97)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169916Effects on liver was determined from serum alanine aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 30+/-3)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID173086Effects on liver was determined from serum cholesterol levels in female (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 0.73+/-0.05)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID190488Serum concentrations of Thyrotropin in rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 11.00+/-1.97)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID190483Serum concentrations of T3 in rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 0.74+/-0.15)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID73847Action potential duration at 50% levels of repolarization in guinea pig papillary muscles after twenty days of daily i.p. injection of 40 mg/kg (Control = 168)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID173088Effects on liver was determined from serum cholesterol levels in male (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 0.67+/-0.13)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID45729Agonism of compound towards thyroid response element (TRAF alpha) in CHO-K1 cells2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID240602Inhibitory activity against human TRAFalpha2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor.
AID190484Serum concentrations of T4 in rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 33.1+/-5.00)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169918Effects on liver was determined from serum alanine aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 30+/-3)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID45734Antagonism of compound towards thyroid response element (TRAF alpha) in CHO-K1 cells2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID173089Effects on liver was determined from serum cholesterol levels in male (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 0.67+/-0.13)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID169786Effects on liver was determined from serum alanine aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 23+/-5)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID173085Effects on liver was determined from serum cholesterol levels in female (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 0.73+/-0.05)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID45731Agonism of compound towards thyroid response element (TRAF beta) in CHO-K1 cells2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID73855Action potential duration at 90% levels of repolarization in guinea pig papillary muscles after twenty days of daily i.p. injection of 40 mg/kg Control = 186)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID77544Effective refractory period in guinea pig papillary muscles after twenty days of daily i.p. injection of 40 mg/kg Control = 201)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID190485Serum concentrations of T4 in rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 33.1+/-5.00)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID190481Serum concentrations of T3 in rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 0.74+/-0.15)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID241132Inhibitory activity against human Thyroid hormone receptor alpha2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor.
AID169947Effects on liver was determined from serum aspartate aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 106+/-18)2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID213170Concentration required to inhibit 50% of binding of [125I]-T3 to human Thyroid hormone receptor alpha-1 in CHO-K1 cells2002Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
AID1346751Human Kv11.1 (Voltage-gated potassium channels)2010European journal of pharmacology, Apr-25, Volume: 632, Issue:1-3
The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (91.67)29.6817
2010's1 (8.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.79 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		4.51701-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
3,3',5-triiodothyroacetic acid
tiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome.		2.0310
3,3',5-triiodothyropropionic acid
[no description available]		2.0310aromatic ether
triiodothyronine
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.		2.43202-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
ibutilide
ibutilide: RN & structure in first source; RN refers to the fumarate salt		2.0210benzenes;
organic amino compound
dronedarone
Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.		2.02101-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
environmental contaminant;
xenobiotic
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		4.82100
kb 141
KB 141: an anticholesteremic agent; structure in first source		2.0310
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid: a thyroid receptor beta1 agonist; structure in first source		2.0310
toxin ii (anemonia sulcata)
toxin II (Anemonia sulcata): toxic polypeptide closely related to anthopleurin A with potent cardiac stimulant activity from Anemonia sulcata; do not confuse with altertoxin II which is also abbreviated ATX II		2.0110
guanosine 5'-o-(3-thiotriphosphate)
Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.		2.0210nucleoside triphosphate analogue
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0110
Auricular Fibrillation
[description not available]		02.0210
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		02.0210
Muscle Relaxation
That phase of a muscle twitch during which a muscle returns to a resting position.		02.0310